Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Street Unsurprised By CRL For Oral Treprostinil, But United Therapeutics’ Stock Tumbles Anyway

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A “complete response” letter from FDA to United’s December NDA for solo therapy of PAH with oral treprostinil certainly will delay and may endanger the Maryland firm’s best near-term growth driver.

You may also be interested in...



Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards

Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.

Looking Long-Term, United Therapeutics Downplays Quarterly Hiccup For Remodulin Franchise

The Maryland-based biotech has been expanding on its lead product line with new formulations and backing it up with strong IP.

Despite Latest Oral Remodulin Phase III Flop, UTHR Says It Still Has Enough Data For FDA

The company tells skeptical analysts it will pursue a limited monotherapy label based on a single positive Phase III study in the wake of a second combination trial failure.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS004988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel